American Regent
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, American Regent sits in the top decile of US sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count).
American Regent: 34 sponsored US clinical trials, none currently recruiting.
American Regent sponsors 34 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 31 completed. 23 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Iron Deficiency Anemia, with 3 trials.
Top-decile sponsor footprint
American Regent ranks in the top decile of sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
31 of 34 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
34 total, page 1 of 1
Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044
NCT04269707
Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA
NCT03523117
Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia
NCT02826681
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study
NCT03037931
Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®
NCT02453334
Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia
NCT02409459
Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS
NCT02397057
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
NCT02492672
Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia
NCT01984554
Pharmacokinetics, Safety, and Efficacy of SPRIX in 12 to 17 Year Old Patients vs. Adult Patients Undergoing Open Surgical Procedures
NCT01819610
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
NCT01290302
Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
NCT00982007
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
NCT00981045
Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
NCT01290315
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
NCT00703937
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
NCT00704028
Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia
NCT00704353
Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects
NCT01365624
Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
NCT00548860
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
NCT00548691
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
NCT00422877
Intravenous Iron Metabolism in Restless Legs Syndrome
NCT00685815
Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients
NCT00354484
Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients
NCT00721188
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
NCT00243867
Taxoprexin® Treatment for Advanced Eye Melanoma
NCT00244816
Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia
NCT00740246
Safety and Efficacy of Iron Sucrose in Children
NCT00239642
Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
NCT00317226
VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
NCT00317239
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding
NCT00395993
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia
NCT00396292
Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
NCT00236977
Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
NCT00087776
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 7 |
| Phase 3 | 22 |
| Phase 4 | 1 |
Therapeutic Areas
How the American Regent archive is shaped
34 indexed studies, none listed as recruiting (0% open); 31 completed (91%).
Phase mix: 23 late (III/IV) vs 9 early (I/II) (later-stage heavy).
Top condition: Iron Deficiency Anemia (3 trials), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
American Regent: archived-pipeline peers nationwide
Peers matched on 34 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
American Regent sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 34 archived trials
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 34 trials · 38% recruiting
- Amicus Therapeutics · 34 trials · 15% recruiting
- Cochlear · 34 trials · 12% recruiting
- Emergent BioSolutions · 34 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this American Regent page
34 registered trials is a research-attention snapshot, not an endorsement of American Regent or any single study.
- None of American Regent's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Iron Deficiency Anemia is the condition American Regent studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Iron Deficiency Anemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
American Regent pipeline card: 34 registered trials from official public datasets.Report a data error.